December 13, 2022:
Citrus Therapeutics co-Founder Presents CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD) at Ophthalmology Innovation Summit XII
Presentation (linked below) highlights this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
November 21, 2022:
Citrus Therapeutics to Present CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD) at Ophthalmology Innovation Summit XII
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, CA – November 18, 2022 – Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
Read the full Press Release:
September 26, 2022:
Citrus Therapeutics Files U.S. Patent for CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD)
A novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, announces that the U.S. Patent Office has issued Patent Application No. 17/837,917 for the “Therapeutic Agent for Treatment of Age-Related Macular Degeneration” and for the registration of the trade name “CTZ1™”, the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and AMD.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ – as a “vascular disruptive agent” – can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
Read the full Press Release:
https://www.prlog.org/12934052-citrus-therapeutics-files-us-patent-for-ctz1-groundbreaking-therapy-for-age-related-macular-degeneration-amd.html
December, 2017: In the December issue of Ophthalmology Management, Citrus Therapeutics is highlighted as a recent finalist in The Winning Pitch Challenge.
The article notes that a “single, under-development product, CTX1, is a novel agent designed for the treatment of both the dry and wet AMD. Its mechanism of action includes both antioxidant activity ideal for oxidative stress encountered in dry AMD and nonselective interference with nicotinic acetylcholine angiogenic pathways that may have utility in both dry and wet forms of AMD.”
Read the entire article here.
August 2017: Citrus Therapeutics were selected as finalists for the inaugural ASRS Winning Pitch Challenge. We presented rationale for our new early phase therapeutic, CTX1, a novel agent for the treatment of age-related macular degeneration. Although we did not win, we are grateful for the feedback and honored to be on stage with a diverse group of innovative retina specialists. The “Shark Tank” atmosphere with a fantastic panel of judges and investors was a lot of fun and we look forward to more in the future.
Ideas. Innovation. Insight.
About / Citrus Therapeutics is an ophthalmic company serving scientists, clinicians, and patients.
For scientists, Citrus focuses on the development of novel therapeutics and technologies and evaluation of novel drugs for the treatment of ocular disease.
For clinicians, Citrus is innovating the way clinical images are shared by developing cloud-based technology solutions. Citrus innovations bring accessibility and collaboration to the forefront of our technology, while preserving patient privacy.
For patients, Citrus seeks to develop an online community by offering a mobile application and website that enables patients with eyes disease to connect, share, and communicate with each other.